Navigation Links
Sunridge Advances its PNT Glaucoma Treatment Throughout China
Date:10/7/2010

FOUNTAIN HILLS, Ariz., Oct. 7 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ) said today that its patented Pneumatic Trabeculoplasty (PNT) non-invasive treatment for glaucoma and ocular hypertension, is making its mark in China.  Introduced into China by Beijing Vision World Trading Co. Ltd. (BVW), in 2007, the PNT treatment has undergone the most vigorous patient research studies before gaining regulatory approval by China's Federal Drug Administration earlier this year.

In recent months, Beijing Vision World had presented the PNT treatment at a number of ophthalmologist conferences, expert forums and hospital training seminars in a number of cities throughout China including Beijing, Nanjing, Taiyuan, Wuhan, Changsha and several towns throughout Northeast China. Research papers devoted to PNT have been presented by leading ophthalmic practitioners and academics at several conferences all of which have been reported in news articles and feature stories appearing in China's general and technical publications.  Details of the treatment and its impact on glaucoma patients, have been featured on national TV programs.  More information regarding these events can be viewed at www.visionworld.com.cn.

In summarizing his firm's progress, Mr. Yang Waisheng, President of BVW, said he and his marketing team were extremely pleased with the reception given by some of China's most demanding ophthalmologists, eye doctors and hospitals throughout China. "We have made a very good start and it is our intention to continue to demonstrate the PNT approach to the treatment of glaucoma.  Our goal is to have PNT taken up by an increasing number of hospitals, clinics and ophthalmic surgeries in China so that we might reach out to as many glaucoma sufferers as possible throughout this vast country.  We are conscious of the fact that many of these patients would otherwise be unable to find treatment to control this pervasive eye disease which is so prevalent in China."

G. Richard Smith, CEO of Sunridge International, said that China represents an enormous marketing opportunity for the PNT equipment and treatment.  "We are delighted with the progress and sales made by Mr. Yang and his team each month and we are determined to provide maximum sales and marketing support to bear on their efforts to bringing our treatment to the tremendous number of outlets in China."CONTACT:Jeff Smith, Sunridge International  T:  +1-480-837-6165e-mail: info@sunridgeint.comwebsite: www.sunridgeint.comMEDIA:Victor Webb, Marston Webb InternationalT: (212) 684-6601e-mail: marwebint@cs.com
'/>"/>

SOURCE Sunridge International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunridge Announces Marketing Roll Out of PNT in the Dominican Republic
2. Sunridge Schedules European Meetings
3. Sunridge Ships First Order to the Middle East
4. Sunridge to Introduce Their PNT Treatment for Glaucoma to Medical Personnel in India
5. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
6. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
7. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
10. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
11. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
Breaking Medicine Technology:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Brady ... announced that its B-595 and B-7569 vinyl label materials received ... and warning labels are tested to remain intact and legible, for use on chemical ...
(Date:4/21/2017)... Portland, Maine (PRWEB) , ... April 21, 2017 ... ... agency, today announced it’s been named Agency of Record (AOR) for Theravent, ... reduce or eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... exciting new partnership with the highly regarded and well renowned Asian distributor, Discovery ... myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home care ... Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business Development. ... agency and our ability to provide quality care to the community,” said Tammara Brown, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal mandate, fines, controversy, ... between the Obamacare program that most Republicans love to hate and Texas Agriculture ... kill hogs. , Like Obamacare, the Miller program centers upon a federal ...
Breaking Medicine News(10 mins):